Analysts expect that Merck & Co., Inc. (NYSE:MRK) will report earnings of $1.52 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Merck & Co., Inc.’s earnings, with the lowest EPS estimate coming in at $1.36 and the highest estimate coming in at $1.59. Merck & Co., Inc. reported earnings per share of $1.74 in the same quarter last year, which indicates a negative year over year growth rate of 12.6%. The company is expected to announce its next earnings report before the market opens on Thursday, October 28th.
According to Zacks, analysts expect that Merck & Co., Inc. will report full-year earnings of $5.51 per share for the current year, with EPS estimates ranging from $5.47 to $5.55. For the next fiscal year, analysts forecast that the firm will report earnings of $6.28 per share, with EPS estimates ranging from $6.08 to $6.52. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.31. The firm had revenue of $11.40 billion during the quarter, compared to analyst estimates of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same period last year, the company posted $1.37 EPS.
Large investors have recently made changes to their positions in the stock. Cowen Prime Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth $31,000. PARK CIRCLE Co raised its holdings in shares of Merck & Co., Inc. by 100.0% during the second quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock worth $31,000 after acquiring an additional 200 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth $37,000. AlphaMark Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth $39,000. Finally, Lake Point Wealth Management purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth $40,000. Institutional investors and hedge funds own 71.83% of the company’s stock.
NYSE MRK traded up $0.56 on Friday, reaching $73.61. 14,713,577 shares of the stock traded hands, compared to its average volume of 11,476,652. The firm’s fifty day simple moving average is $75.80 and its 200 day simple moving average is $76.52. The company has a quick ratio of 1.06, a current ratio of 1.31 and a debt-to-equity ratio of 0.72. The company has a market cap of $186.33 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 2.16 and a beta of 0.41. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $85.60.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be issued a dividend of $0.65 per share. The ex-dividend date is Tuesday, September 14th. This represents a $2.60 annualized dividend and a dividend yield of 3.53%. Merck & Co., Inc.’s dividend payout ratio is 43.77%.
About Merck & Co., Inc.
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.